Best Candidates for HER2-Directed ADCs in HR+/HER2-Low Metastatic Breast Cancer
Experts on breast cancer describe the best candidates for HER2-directed antibody-drug conjugates in HR+/HER2-low metastatic breast cancer, highlighting the role of trastuzumab deruxtecan in later lines of therapy.
Video content above is prompted by the following questions:
- Which patients are most suitable for a HER2-directed antibody-drug conjugate (ADC) in HR+/HER2-low metastatic breast cancer?
- Would you consider trastuzumab deruxtecan for second-line therapy or as a later line?
T-DXd Use in HER2+ Breast Cancer Influenced by Site of Metastases and AE Monitoring
October 21st 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
